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Abstract
Background. Inhibitors of fibroblast growth factor receptors (FGFRs) have recently arisen as a promising treat-
ment option for patients with FGFR alterations. Gene fusions involving FGFR3 and transforming acidic coiled-coil 
protein 3 (TACC3) have been detected in diffuse gliomas and other malignancies, and fusion-positive cases have 
responded well to FGFR inhibition. As high FGFR3 expression has been detected in fusion-positive tumors, we 
sought to determine the clinical significance of FGFR3 protein expression level as well as its potential for indicat-
ing FGFR3 fusions.
Methods. We performed FGFR3 immunohistochemistry on tissue microarrays containing 676 grades II–IV astrocy-
tomas and 116 grades II–III oligodendroglial tumor specimens. Fifty-one cases were further analyzed using targeted 
sequencing.
Results. Moderate to strong FGFR3 staining was detected in gliomas of all grades, was more common in females, 
and was associated with poor survival in diffuse astrocytomas. Targeted sequencing identified FGFR3-TACC3 
fusions and an FGFR3-CAMK2A fusion in 10 of 15 strongly stained cases, whereas no fusions were found in 36 
negatively to moderately stained cases. Fusion-positive cases were predominantly female and negative for IDH 
and EGFR/PDGFRA/MET alterations. These and moderately stained cases show lower MIB-1 proliferation index 
than negatively to weakly stained cases. Furthermore, stronger FGFR3 expression was commonly observed in 
malignant tissue regions of lower cellularity in fusion-negative cases. Importantly, subregional negative FGFR3 
staining was also observed in a few fusion-positive cases.
Conclusions. Strong FGFR3 protein expression is indicative of FGFR3 fusions and may serve as a clinically appli-
cable predictive marker for treatment regimens based on FGFR inhibitors.
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Glioma pathology has recently experienced great advance-
ments as sequencing studies by the working group of 
The Cancer Genome Atlas1,2 and others3,4 have identified 
new molecular criteria for the diagnosis and stratifica-
tion of gliomas. The World Health Organization recently 
published new definition criteria for glioma diagnosis.5 
Diffuse gliomas can be currently stratified into 3 main cat-
egories based on isocitrate dehydrogenase (IDH) muta-
tion status and the presence of 1p/19q codeletion.1–4 IDH 
wild-type tumors, which are present in all diffuse glioma 
grades, have usually the poorest survival rates and are 
generally less responsive to treatment,6 highlighting the 
need for better treatment options for these patients. Since 
the discovery of recurrent fibroblast growth factor recep-
tor (FGFR) gene fusions in glioblastoma (GBM),7,8 targeted 
treatment regimens using FGFR inhibitors have arisen as 
a promising option for glioma patients with FGFR altera-
tions. Of those, oncogenic FGFR3 fusions and various 
FGFR1 alterations have been detected in brain tumors.7–14 
In addition, FGFR fusions and other FGFR alterations have 
been detected in several extracranial malignancies.10,15–20 
FGFR3 is most commonly fused to the transforming acidic 
coiled-coil protein 3 gene (TACC3), but other fusion part-
ners also exist, such as recurrent FGFR3–BAIAP2L1 fusions 
in bladder cancer.18 Several FGFR inhibitors are currently 
being tested in clinical trials for different cancer types,21 
and FGFR3 fusion-positive cells and tumors show the 
best treatment responses.18,22 Responses to FGFR inhibi-
tor treatment have also been reported in GBM.9,22 Tumors 
that carry FGFR3 fusions or other responsive FGFR altera-
tions represent a minority of cases in these malignancies, 
which emphasizes the need for efficient patient stratifica-
tion tools, as also stated by others.23
We have previously shown that FGFR3 protein expres-
sion is suppressed by miR-99a, one of the most abundantly 
expressed miRNAs in gliomas and normal brain tissue.8 
High fusion protein levels have been reported in GBM,8,9 
most likely because the miR-99a binding site is removed 
by genomic rearrangements that generate FGFR3 fusions.8 
The miR-99a–mediated suppression of FGFR3 may explain 
why activating FGFR3 mutations are not observed in dif-
fuse gliomas. The relationship between FGFR3 immu-
nostaining intensity and fusion status or FGFR3 expression 
levels in fusion-negative cases has not been systematically 
analyzed before. We wanted to determine whether strong 
FGFR3 staining, detected using an antibody that recognizes 
an epitope present in all reported gene fusions, could be 
used as a marker for FGFR3 gene fusion. We therefore used 
immunohistochemistry (IHC) to detect FGFR3 in 791 dif-
fuse glioma cases and associated FGFR3 expression with 
patients’ clinical features. Genetic alterations in FGFR3 and 
other glioma-associated genes were identified by targeted 
sequencing of selected cases. Our results demonstrate that 
strong FGFR3 staining characterizes FGFR3 fusion-positive 
diffuse gliomas. FGFR3 fusions involved several fusion 
partners, junctions, and breakpoints, rendering them diffi-
cult to detect in a comprehensive manner with PCR-based 
methods in a diagnostic context.
Materials and Methods
Patient Tissue Samples
The study design was approved by the ethical committee 
of Tampere University Hospital and the National Authority 
for Medicolegal Affairs in Finland. Diffuse glioma samples 
had been obtained from tumor surgery patients at Tampere 
University Hospital between 1983 and 2009 and diagnosed 
according to the World Health Organization (WHO) 2007 
classification for this study. We used 676 diffuse astrocy-
toma samples and 116 oligodendroglial tumors for FGFR3 
detection (Table 1). Cause-specific survival association of 
grades II–IV diffuse astrocytomas was analyzed using pri-
mary tumors (n =  533) (Table 1, Supplementary Table 1). 
The samples were fixed in formaldehyde (buffered with 4% 
phosphate), embedded in paraffin, and processed for tis-
sue microarray (TMA).24
In the 2016 WHO classification, IDH mutation and 1p/19q 
codeletion are used as additional criteria for more detailed 
diffuse glioma diagnosis. In our cohort, 113 astrocyto-
mas (20%, 562 analyzed) and 79 oligodendroglial tumors 
(81%, 97 analyzed) were positive for IDH p.R132H. The 
1p/19q codeletion was detected in 28 (90%, 31 analyzed) 
of IDH p.R132H positive-staining oligodendroglial tumors 
using fluorescence in situ hybridization.25 Our cohort thus 
includes 96 IDH-mutant diffuse astrocytomas, 40 IDH-
mutant GBMs, and 28 oligodendrogliomas (IDH-mutant 
and 1p/19q codeleted) according to the WHO 2016 crite-
ria. The remaining tumors with inconclusive genetic test-
ing are classified as diffuse astrocytoma, not otherwise 
Importance of the study
FGFR3 gene fusions, initially discovered in glioblas-
toma, have since been reported in a wide spectrum 
of other malignancies. FGFR3 fusion-positive tumors 
have responded well to FGFR inhibitors in ongoing 
clinical trials. We demonstrate that FGFR3 staining 
is negative in most diffuse gliomas, whereas strong 
FGFR3 staining is observed in all fusion-positive 
cases, which facilitates stratification of FGFR3 fusion-
positive gliomas. FGFR3 immunostaining does not 
rely on prior knowledge about fusion breakpoints 
or partners and allows evaluation of intratumoral 
heterogeneity by revealing heterogeneous expres-
sion levels and FGFR3-negative subclones. Fusions 
were only detected in aggressive isocitrate dehydro-
genase wild-type tumors and were more common 
in female patients. Interestingly, moderate to strong 
FGFR3 staining was associated with a lower MIB-1 
proliferation index without any prognostic benefit. The 
obtained information is relevant when FGFR3 fusions 
are targeted for therapeutic purposes and for better 
understanding of FGFR3 fusion-driven tumor develop-
ment and progression.
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specified (NOS) (80 tumors), oligodendroglioma, NOS (48 
tumors), oligoastrocytoma, NOS (37 tumors), and glioblas-
toma, NOS (463 tumors).
Immunohistochemistry Staining
We stained 24 TMA slides using mouse monoclonal 
FGFR3 antibody (1:600 dilution; #sc-13121, Santa Cruz 
Biotechnology) together with the Dako EnVision+ kit 
(K4006) and antibody diluent S0809. Antigen retrieval was 
performed in sodium citrate buffer (pH 6.0), and immun-
operoxidase reactions were visualized with 3,3'-diamin-
obenzidine using hematoxylin for counterstaining. IDH 
p.R132H, MIB-1, and p53 staining have been reported pre-
viously.26,27 An experienced neuropathologist (H.H.) and 
an experienced cell biologist (K.G.) independently scored 
FGFR3 IHC staining intensities as 0 (no staining), 1 (weak), 
Table 1 Patient demographic and clinical characteristics in the astrocytic and oligodendroglial tumor cohorts*
Astrocytoma Grade II Grade III Grade IV All
No. of patients 114 59 503 676
Sex (n)
Male 82 38 287 407
Female 32 21 216 269
Age, y
Median (mean ± SD) 46 (46 ± 16) 50 (52 ± 17) 65 (65 ± 13)
Minimum 12 23 4
Maximum 83 84 90
Follow-up
No. of survivors at the end of follow-up 25 6 9
Follow-up duration for survivors, mo (median [mean ± SD]) 92 (108 ± 77) 141 (142 ± 80) 59 (98 ± 69)
5-y survival rate, % 58 32 3.4
Tumors (n)
Primary 81 41 414
Second recidive 25 13 69
Third recidive 8 4 17
Fourth-sixth recidive 0 1 2
Oligodendroglial tumor O II O III OA II OA III
No. of patients 38 33 23 22
Sex (n)
Male 19 17 12 8
Female 19 16 11 14
Age, y
Median (mean ± SD) 45 (45 ± 12) 57 (57 ± 10) 52 (46 ± 17) 42 (46 ± 15)
Minimum 26 38 5 25
Maximum 69 72 64 74
Follow-up
No of survivors at the end of follow-up 25 9 9 4
Follow-up duration for survivors, mo (median [mean ± SD]) 83 (106 ± 64) 96 (66 ± 50) 94 (161 ± 121) 203 (221 ± 114)
5-y survival rate, % 79 43 84 50
Tumors (n)
Primary 34 21 19 18
Second recidive 4 10 4 4
Third recidive 0 1 0 0
Fourth-sixth recidive 0 1 0 0
Abbreviations: O, oligodendroglioma, OA, oligoastrocytoma.
*Patient age and follow-up information were calculated using primary cases. Follow-up times are shown in months (mo). 
2 (moderate), or 3 (strong staining). Consensus interpre-
tation was used in the case of discrepant interpretation. 
MIB-1 staining on TMAs was used for the proliferation 
analysis.
For antibody blocking, either peptide corresponding to full-
length epitope (amino acids 25–124 of FGFR3 of human origin) 
(Biocenter Finland Protein Service) or peptide corresponding 
to amino acids 40–64 (GPEPGQQEQLVFGSGDAVELSCPPP) 
(GenScript) efficiently blocked antibody staining. Antibody 
was incubated (30 min room temperature) with or without 
the excess blocking peptide (5 times the antibody concen-
tration in ng/µL units) in antibody diluent before adding the 
mixture onto slides.
Statistical Methods
Statistical analyses were performed using R or IBM SPSS 
statistics 21.0 software for Windows. For tables larger than 
2 × 2, the P-values of Fisher’s exact test were calculated 
using Monte Carlo simulation with 2.5*107replicates.
Targeted Sequencing
Fifty-one samples with staining data from whole-mount 
tissue samples were analyzed using pulldown-based tar-
geted sequencing. These included 15 strongly stained, 
22 moderately stained, 6 weakly stained, and 8 nega-
tively stained samples. Most samples were formalin 
fixed and paraffin embedded (FFPE). The turXTRAC FFPE 
DNA kit (Covaris) or AllPrep DNA/RNA Mini Kit (Qiagen) 
was used for DNA isolation. The QIAamp DNA Mini Kit 
(Qiagen) was used for 4 freshly frozen GBM samples that 
were available. Target regions were enriched for sequenc-
ing from 1 μg of extracted DNA using the Sureselect XT 
Target enrichment system and custom-designed RNA 
probes (Supplementary Table  2). The sequencing librar-
ies were prepared according to the kit (200  ng of DNA 
samples) with a shorter DNA-shearing protocol (220 sec) 
and were sequenced with an Illumina MiSeq instrument. 
Reads were aligned against the GRCh37 human reference 
genome using Bowtie-2.2.4.28
Somatic Mutation Calling and Fusion Detection
Somatic mutations were called by searching for variants 
with an alternate allele fraction of at least 10%, and at least 
5 supporting reads. Additionally, the allele fraction was 
required to be 20 times higher than the background error 
rate (ie, the average allele fraction across all nontumor 
samples). Variants with a population frequency of 0.5% or 
above in the 1000 Genomes or ESP6500 database were 
filtered out. Protein-level outcomes were predicted using 
ANNOVAR.29 To discover chromosomal rearrangements 
for fusion detection, unaligned reads from each sample 
were split into two 30 bp anchors (one from both ends) 
that were aligned to the hg38 genome using Bowtie-1.1.2. 
Discordant anchor pairs were grouped by position, and 
groups with 8 or more supporting reads were flagged as 
rearrangement candidates and manually curated using 
IGV and BLAT.
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2 (moderate), or 3 (strong staining). Consensus interpre-
tation was used in the case of discrepant interpretation. 
MIB-1 staining on TMAs was used for the proliferation 
analysis.
For antibody blocking, either peptide corresponding to full-
length epitope (amino acids 25–124 of FGFR3 of human origin) 
(Biocenter Finland Protein Service) or peptide corresponding 
to amino acids 40–64 (GPEPGQQEQLVFGSGDAVELSCPPP) 
(GenScript) efficiently blocked antibody staining. Antibody 
was incubated (30 min room temperature) with or without 
the excess blocking peptide (5 times the antibody concen-
tration in ng/µL units) in antibody diluent before adding the 
mixture onto slides.
Statistical Methods
Statistical analyses were performed using R or IBM SPSS 
statistics 21.0 software for Windows. For tables larger than 
2 × 2, the P-values of Fisher’s exact test were calculated 
using Monte Carlo simulation with 2.5*107replicates.
Targeted Sequencing
Fifty-one samples with staining data from whole-mount 
tissue samples were analyzed using pulldown-based tar-
geted sequencing. These included 15 strongly stained, 
22 moderately stained, 6 weakly stained, and 8 nega-
tively stained samples. Most samples were formalin 
fixed and paraffin embedded (FFPE). The turXTRAC FFPE 
DNA kit (Covaris) or AllPrep DNA/RNA Mini Kit (Qiagen) 
was used for DNA isolation. The QIAamp DNA Mini Kit 
(Qiagen) was used for 4 freshly frozen GBM samples that 
were available. Target regions were enriched for sequenc-
ing from 1 μg of extracted DNA using the Sureselect XT 
Target enrichment system and custom-designed RNA 
probes (Supplementary Table  2). The sequencing librar-
ies were prepared according to the kit (200  ng of DNA 
samples) with a shorter DNA-shearing protocol (220 sec) 
and were sequenced with an Illumina MiSeq instrument. 
Reads were aligned against the GRCh37 human reference 
genome using Bowtie-2.2.4.28
Somatic Mutation Calling and Fusion Detection
Somatic mutations were called by searching for variants 
with an alternate allele fraction of at least 10%, and at least 
5 supporting reads. Additionally, the allele fraction was 
required to be 20 times higher than the background error 
rate (ie, the average allele fraction across all nontumor 
samples). Variants with a population frequency of 0.5% or 
above in the 1000 Genomes or ESP6500 database were 
filtered out. Protein-level outcomes were predicted using 
ANNOVAR.29 To discover chromosomal rearrangements 
for fusion detection, unaligned reads from each sample 
were split into two 30 bp anchors (one from both ends) 
that were aligned to the hg38 genome using Bowtie-1.1.2. 
Discordant anchor pairs were grouped by position, and 
groups with 8 or more supporting reads were flagged as 
rearrangement candidates and manually curated using 
IGV and BLAT.
Copy Number Analysis
Read counts were calculated using Bedtools-2.25.0.30 
At least 25% of a read was required to be within the tar-
geted capture region for the read to be counted. For each 
sample, we calculated coverage log ratios at all captured 
regions against a median reference derived from gender-
matched blood samples from healthy patients (2 for each 
gender). We then corrected for guanine-cytosine content 
bias in coverage log ratios using a Theil–Sen estimator 
(after observing that guanine-cytosine content and cover-
age log ratio bias had a linear relationship in this cohort) 
(Supplementary Figure  1). Finally, we forced the median 
log ratio of control baits in infrequently copy number 
altered chromosomes 5, 8, 11, and 18 to zero by subtracting 
the median from all log ratios. Copy numbers were called 
by visual inspection of violin plots that visualize coverage 
log ratios for each target gene.
Computational Analysis of FGFR3 IHC Staining
FGFR3 staining intensities were computationally analyzed 
from whole-mount FFPE tissue samples of cases that 
were used for targeted sequencing. One to 3 representa-
tive regions of interest (size 1.4–52 mm2, average 9.7 mm2) 
were selected from scanned tissue images. Red versus 
blue ratio, which was used as a readout of staining inten-
sity, was calculated for each pixel in the regions of interest. 
To remove background and nuclear hematoxylin staining, 
only pixels with a red/blue ratio ≥1.00 were included in the 
analysis. The mean of red/blue ratios was calculated from 
these pixel locations.
Results
Moderate to Strong FGFR3 Staining Associated 
with Poor Survival and Absence of IDH1 p.R132H 
Mutation
We used an antibody that targets amino acids 25–124 in 
the FGFR3 N-terminus to perform IHC staining on 676 
diffuse astrocytomas and 116 grades II–III oligodendro-
glial tumors (Table  1). Moderate to strong FGFR3 stain-
ing was generally diffuse and cytosolic with occasional 
nuclear staining, whereas membrane-restricted staining 
was observed in some of the more weakly stained cases 
(Fig.  1A, Supplementary Figure  2). Negatively stained 
blood vessels provided an internal control for antibody 
specificity (Supplementary Figure 3a). Normal brain tissue 
was generally negative, with the exception of the cerebel-
lar and cerebral molecular layers, where weak to moder-
ate staining was observed (Supplementary Figure 3B–C). 
Among astrocytomas, 575 (85%) cases were fully negative 
for FGFR3. Among samples with FGFR3 immunoreactivity, 
68 (10%) showed weak, 21 (3.1%) moderate, and 12 (1.8%) 
strong positivity. The proportion of moderately to strongly 
stained cases was within the range of previous estimates of 
FGFR3 fusion frequency.1,2,7,8 FGFR3 staining was not asso-
ciated with tumor grade (Fig. 1B). Among 116 oligodendro-
glial tumors, only 2 cases (1.7%) exhibited moderate and 1 
Downloaded from https://academic.oup.com/neuro-oncology/article-abstract/19/9/1206/3098170/Strong-FGFR3-staining-is-a-marker-for-FGFR3
by Tampere University Library. Department of Health Sciences user
on 25 August 2017
 1210 Granberg et al. Strong FGFR3 staining marks FGFR3 fusions
Fig. 1 Moderate or strong FGFR3 staining was associated with worse survival and lack of IDH1 p.R132H mutation. (A) Representative staining 
images. Proportion of samples for each staining category in grades II–IV astrocytomas is indicated below the representative images. Scale bars: 
100 µm in 40×, 20 µm in 200×, and 10 µm in 400× images. (B) FGFR3 staining distribution in grades II–IV astrocytomas was not associated with tumor 
grade (P = .523, Fisher’s exact test). (C) Moderate or strong FGFR3 staining was associated with poor cause-specific survival (n = 533, P = .042, 
log-rank test). (D) Moderate to strong FGFR3 staining was more common in IDH1 p.R132H staining-negative cases. Each sample is marked with a 
circle and colored according to FGFR3 staining. IDH1 p.R132H-negative GBM samples included 159 females and 215 males; thus, all the negatively 
to weakly stained cases are not visualized separately. **P < .01, Fisher’s exact test. A: astrocytoma, O: oligodendroglioma, OA: oligoastrocytoma.
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case (0.9%) strong FGFR3 staining; all 3 cases were grade II 
(Supplementary Figure 4).
An association analysis of astrocytic tumors (Suppl-
ementary Figure  5) revealed that moderate to strong 
FGFR3 staining was more common in females (8.55%) than 
in males (2.46%) (P < .001, Fisher’s exact test) and less com-
mon in samples with aberrant p53 expression (P < .010, 
Fisher’s exact test) (Supplementary Figure 6). In the prog-
nostic analysis, moderate and strong FGFR3 staining was 
associated with a significantly shorter cause-specific sur-
vival duration than weak and negative staining (P = .0417, 
n = 533, log-rank test) (Fig. 1C). Although the association 
remained significant after adjustment for grade, prolifera-
tion, and IDH1  p.R132H mutation status (P  =  .0422, Cox 
proportional hazards model) (Supplementary Table 3), no 
significant associations were observed when analysis was 
restricted to grade IV GBM (P = .203, n = 414, log-rank test) 
or cases lacking IDH1 p.R132H mutation (P = .119, n = 370 
for grades II–IV astrocytomas and P  =  .525, n =  343 for 
GBMs, log-rank test) (Supplementary Figure 7), suggesting 
that the reduced survival of moderately to strongly stained 
cases is at least partly explained by their IDH1 mutation 
status and high proportion of glioblastoma tumors. Indeed, 
moderate to strong FGFR3 staining was only observed in 
patients who lacked IDH1 p.R132H mutation, and all except 
one of them suffered from GBM in the survival analysis 
(Supplementary Figure  8). In the whole diffuse glioma 
cohort, we found only 3 IDH1 p.R132H–positive cases with 
moderate and none with strong FGFR3 staining (P = .0063, 
Fisher’s exact test, for the IDH1 p.R132H staining associa-
tion) (Fig. 2D, Supplementary Figure 9). The immunostain-
ing results strongly coincide with previously reported 
data on FGFR3 fusion-positive tumors (Supplementary 
Figure 10),1,2,8,9 supporting the use of IHC for FGFR3 fusion 
detection.
FGFR3 Staining Is Spatially Heterogeneous
Next, we performed FGFR3 staining on all the available 
whole-mount tissue samples with moderate to strong 
FGFR3 staining on TMA. In addition, a subset (11%) of GBM 
samples with negative to weak staining on TMA were ana-
lyzed using whole-mount tissue sections. Heterogeneous 
FGFR3 staining of malignant tissue was generally observed 
(Fig.  2A). Strong staining was subregional, and staining 
intensities typically varied in a continuous fashion. Most 
samples (65%, n = 114) had the same FGFR3 staining score 
Fig. 2 FGFR3 staining is heterogeneous. (A) Representative images (50× magnification) of heterogeneously stained areas in 3 cases with strong 
FGFR3 staining. In sample GBM-05, the staining pattern clearly differed between tumor sites. Scale bar 50 µm. (B) Summary of FGFR3 IHC staining 
data from whole-mount tissue slides. Most samples (65% of all) retain their original FGFR3 staining score evaluated from TMA data, but especially 
moderate scoring was observed in many samples (21% of all) with negative to weak staining on TMA. Numbers of TMA samples, whole-mount 
tissue samples used for staining, IDH1 p.R132H staining-positive samples, and GBM samples are marked on the left-hand side. On the right, shown 
are the number of whole-mount tissue samples and their proportion of all the stained slides with the specified staining score on TMAs.
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on both the TMA and the whole-mount tissue slide (Fig. 2B), 
but higher staining intensities were observed in one third 
of the samples. It is thus better to perform FGFR3 staining 
for diagnostic purposes using whole-mount tissue slides, as 
they will be more representative than biopsies or TMAs.
Cases with Strong FGFR3 Staining Harbor FGFR3 
Fusion Rearrangements
To detect genomic breakpoints in cases with positive FGFR3 
staining, we selected 51 diffuse glioma samples (includ-
ing 43 GBMs, 5 grade II astrocytomas, 2 grade II oligoas-
trocytomas, and 1 grade II oligodendroglioma according 
to initial diagnosis) for targeted sequencing. We analyzed 
all the patients with moderate to strong FGFR3 staining in 
whole-mount tissue slides and with enough tumor mate-
rial for sequencing, but the cohort included also negatively 
to weakly stained cases. In addition to FGFR3 and FGFR1, 
the sequencing panel targeted genes with reported altera-
tions in diffuse gliomas, such as IDH1, IDH2, TP53, ATRX, 
CIC, FUBP1, CDKN2A, and RB1. FGFR3 rearrangements 
that generated gene fusions were detected in 10 cases 
(Fig. 3A, Supplementary Table 4), including 9 FGFR3-TACC3 
fusions and 1 FGFR3-CAMK2A fusion. In addition, case 
GBM-19 harbored an FGFR3 copy number gain (Fig.  3A) 
and a rearrangement that joined the WHSC1 gene, located 
downstream of FGFR3, to TACC3 (data not shown). The 
DNA breakpoints and resulting FGFR3 fusion junctions 
were distinct in each tumor (Fig.  3C, Supplementary 
Figure 11), but the coiled-coil domain of TACC3 was con-
served in FGFR3-TACC3 fusions. CAMK2A codes for a 
subunit of calcium/calmodulin-dependent protein kinase 
II (CAMK2).31,32 The C-terminal self-association domain of 
CAMK2A is joined with nearly the full-length FGFR3 pro-
tein.31,32 This is also the case for the fusion of FGFR3 and 
embryonic lethal abnormal vision (ELAV)–like RNA bind-
ing protein 3 (ELAVL3) previously reported in oligoastro-
cytoma1,33 (Supplementary Figure 10). It is thus likely that 
ELAVL3 and CAMK2A facilitate spontaneous fusion protein 
oligomerization and drive the oncogenic activity of FGFR3 
fusion through increased kinase activity, as suggested for 
previously reported FGFR3 fusions.18,19
Most positive cases were GBMs, but FGFR3-TACC3 
fusion rearrangements were also found in one grade II 
tumor with astrocytic morphology and one grade II tumor 
with oligoastrocytic morphology. Both cases were IDH 
wild-type in targeted sequencing, and thus represent 
“diffuse astrocytoma, IDH wild-type” in the WHO 2016 
classification.5 This is also the case for the IDH wild-type 
grade II tumors ASTRO-02 and OASTRO-02, which showed 
strong FGFR3 staining but did not carry detectable FGFR3 
fusions.
All FGFR3-TACC3 and FGFR3-CAMK2A fusion-positive 
samples were strongly FGFR3 positive on IHC (stain-
ing sensitivity 100% in sequencing cohort) (Fig.  3A, 
Supplementary Figure 12). Five cases (out of 41, staining 
specificity 88% in the sequencing cohort) lacked inter-
genic FGFR3 rearrangements but showed strong FGFR3 
staining in subregions of whole tissue sections (Fig.  3A, 
Supplementary Figure  12). Computationally analyzed 
staining intensities were also significantly higher in fusion-
positive cases than in negatively to moderately stained 
fusion-negative cases (P < .0001, Kruskal–Wallis test) 
(Fig.  3A–B). Fusion-negative cases that show only focal 
strong FGFR3 staining (GBM-09, GBM-10, and ASTRO-02) 
resemble more moderately stained cases in the computa-
tional analysis (Fig. 3A–B).
FGFR3 Fusion-Positive Cases Are Predominantly 
Female and Mutually Exclusive with EGFR/
PDGFRA/MET Alterations
All cases with FGFR3 fusions were IDH wild-type, which 
is concordant with the results of previous reports.7,9 In 
addition, FGFR3 fusion events were mutually exclusive 
with amplification or mutation of epidermal growth fac-
tor receptor (EGFR)/platelet derived growth factor recep-
tor alpha (PDGFRA)/MET (Fig. 3A, Supplementary Tables 
4–5). Mutual exclusivity between EGFR amplification and 
FGFR3-TACC3 fusions has been previously reported by us 
and others.8,9
Nearly all patients (7 of 8)  with FGFR3-TACC3 fusions 
were female, the sole exception being a male patient 
with grade II oligoastrocytoma. Alternative FGFR3-
CAMK2A and FGFR3-ELAVL31 fusions were observed 
in male patients. A  higher FGFR3 fusion frequency in 
females (P =  .028, Fisher’s exact test) (Fig. 3B) is consist-
ent with sex-associated FGFR3 staining distribution in 
our IHC cohort (Supplementary Figure  6a). In all previ-
ously reported cohorts, 14 females and 11 males carried 
FGFR3 fusions.1,2,8,9,13,34 After combining our data and all 
IDH wild-type cases with sex information in previous repo
rts,1,2,8,13,34 3.1% of males (8 of 255) and 8.4% of females (14 
of 152) were FGFR3 fusion positive (P = .027, Fisher’s exact 
test), suggesting a higher incidence among females.
Predominant FGFR3 Staining Typically Observed 
in Fusion-Positive Tumors
As negative FGFR3 staining was commonly observed in 
whole-mount tissue slide samples, we determined the pro-
portion of positively (weakly to strongly) stained malignant 
cells from the tissue slide samples. In 6 of 9 fusion-positive 
patients, all malignant cells were FGFR3 positive (Fig. 4B). 
Moderate to strong staining was observed in 4 cases and 
weak to strong staining in 2 cases. Furthermore, both GBM-
04 and GBM-07 samples, derived from different surgeries 
of one patient, had a small negatively stained tumor region 
(<10% of malignant cells). There was a significant propor-
tion of negatively stained malignant cells in 2 additional 
fusion-positive patients (GBM-02 and GBM-05). These 
cases harbored an FGFR3-CAMK2A fusion and an FGFR3-
TACC3 fusion, in which the breakpoint was in the 3' untrans-
lated region (UTR) of FGFR3 but produced fusion protein, 
as the splicing acceptor site had been deleted during the 
rearrangement (Supplementary Figure 13). The proportion 
of positively stained malignant cells was higher in fusion-
positive than fusion-negative samples (P  =  1.2  ×  10–8, 
Fisher’s exact test) (Fig.  4A), suggesting that positive 
staining in the whole malignant tissue further supports 
the presence of FGFR3 fusion. The majority of FGFR3-
positive malignant cells were moderately to strongly 
stained in all fusion-positive cases, which is concordant 
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Fig. 3 FGFR3 fusion-positive cases showed strong FGFR3 staining. Most were female and lacked alterations in IDH, EGFR, and PDGFRA genes. 
(A) FGFR3 rearrangements and associated alterations were detected by targeted sequencing. FGFR3 staining scores (3: strong, 2: moderate, 1: 
weak, 0: negative staining) on whole-mount tissue slides and computational analyzed staining intensities are marked above the aberration matrix. 
The cases had been initially diagnosed as GBMs (one giant cell glioblastoma [GC] and 2 gliosarcomas [GS]), grade II astrocytomas (A), grade II 
oligoastrocytomas (OA), and a grade II oligodendroglioma (O). M: male, F: female. (B) Computationally analyzed FGFR3 staining intensity is signifi-
cantly higher in fusion-positive cases than in negatively to moderately stained fusion-negative cases (P < .0001, Kruskal–Wallis test). Cases with 
focal strong FGFR3 staining are marked in red. (C) FGFR3 fusions were more commonly observed in females than in males (*P < .05, Fisher’s exact 
test). (D) All FGFR3 fusion partners carried dimerization domains. Predicted fusion protein structures are shown in the figure. Intronic regions that 
become part of the translated fusion protein are marked with gray. *In-frame fusion junction is located inside the marked exon.
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with moderate to strong FGFR3 staining observed in all the 
fusion-positive cases on TMA. The use of antibody block-
ing peptide diminished FGFR3 staining very efficiently in 
both fusion-positive and fusion-negative tumors, as only 
red blood cell and hemosiderin staining were apparent 
in samples that were stained by using a blocking peptide 
(Supplementary Figure 14).
Higher FGFR3 Staining Was Associated with 
Lower Proliferation Rate
We next associated FGFR3 staining data with the propor-
tion of MIB-1 immunopositive nuclei, which is commonly 
used as a cell proliferation index and a key feature of 
tumor aggressiveness. Surprisingly, astrocytoma cases 
with moderate to strong FGFR3 staining exhibited lower 
proliferation rates than negatively or weakly stained cases 
independently of tumor grade (P < .05, Kruskal–Wallis test) 
(Supplementary Figure 15a). This is somewhat contradic-
tory to worse prognosis of moderately to strongly stained 
cases in the same cohort (Fig. 1C). A similar pattern was 
also observed in whole-mount tissue GBM samples used 
for FGFR3 staining (P = .0048, Kruskal–Wallis test) (Fig. 4B, 
Supplementary Figure  15b). Staining was not associated 
with patient prognosis in this cohort (Supplementary 
Figure  16). Lower proliferation rates of FGFR3 fusion-
positive tumors may have led to underestimation of their 
aggressiveness when diagnosis was based on WHO 2007 
classification. More detailed inspection of intratumoral 
FGFR3 staining patterns revealed that stronger FGFR3 
staining was observed in less cellular tumor areas with 
higher differentiation state in a large proportion of fusion-
negative cases but not in fusion-positive cases (P =  .024, 
Fisher’s exact test) (Fig. 4C, Supplementary Figure 17). In 
addition, stronger FGFR3 staining was perivascular in a 
subpopulation of cases (Supplementary Figure  3a), but 
this was not associated with fusion status.
Discussion
Our results demonstrate that FGFR3 staining, as detected 
using IHC, is indicative of FGFR3 gene fusion, which can be 
further confirmed by PCR- or sequencing-based technolo-
gies. This method allows efficient patient selection, as most 
cases are fully negative for FGFR3, and is fully compatible 
with current clinical practices throughout the world. Even 
if sequencing-based technologies are used as the primary 
tool for FGFR3 fusion detection, information on fusion pro-
tein expression levels will be valuable when estimating 
FGFR inhibitor treatment response. FGFR3 alterations will 
not be informative if the altered protein is not expressed. 
Actually, FGFR1 expression levels have been shown to 
predict treatment responses better than genomic FGFR1 
alterations in head and neck squamous cell cancers as well 
as different lung cancers.35,36 The role of FGFR3 staining as 
an independent predictive marker needs to be evaluated in 
the future. We identified 2 IDH wild-type cases with strong 
and widely positive FGFR3 staining but no evidence for 
intergenic FGFR3 rearrangements (Fig.  3A). It is relevant 
to determine whether these cases will benefit from treat-
ment with FGFR inhibitors. Reason for strong FGFR3 stain-
ing in fusion-negative samples is unknown, but at least the 
miR-99a gene was not altered in these tumors. One reason 
might be suppressed miR-99a expression, despite miR-99a 
Fig. 4 (A) The proportion of negatively stained tumor cells was gen-
erally lower in fusion-positive cases. P = 1.2 × 10–8, Fisher’s exact test. 
(B) Tumors with moderate to strong FGFR3 staining showed lower 
proliferation rate than negatively to weakly stained tumors (P = .0048, 
Kruskal–Wallis test). FGFR3 fusion-positive cases significantly dif-
fered from fusion-negative ones (P = .032, Mann–Whitney test). GBM 
samples with whole-mount tissue staining of FGFR3 were included 
in the analysis. Out of strongly stained samples, only fusion-positive 
cases were included due to low number of fusion-negative ones. The 
mean proliferation rate observed on TMA and SEM are shown. (C) 
FGFR3 staining was associated with lower cellularity within malig-
nant regions in whole-mount tissue sections used for targeted 
sequencing, but this association was not observed in FGFR3 fusion-
positive cases (P = .024, Fisher’s exact test).
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being clearly expressed in all the GBMs in the cohort of 
The Cancer Genome Atlas. Atypical oncogenic rearrange-
ments, such as intragenic rearrangements in FGFR1,12 may 
also be difficult to detect, which might cause false nega-
tives in sequencing analysis.
Our sequencing cohort does not fully represent the 
original staining cohort, as we sequenced all available 
moderately to strongly stained tumors but only part of 
the negatively to weakly stained tumors. This was done 
for practical reasons, as moderate FGFR3 fusion recur-
rence rate requires a large cohort for fusion analysis, 
but pulldown-based targeted sequencing expenses and 
workload are not compatible with hundreds of samples. 
Our approach allowed us to estimate staining sensitivity 
and specificity only in the sequencing cohort. Sensitivity 
was 100%, which is consistent with previous studies, 
where we and others have detected strong FGFR3 stain-
ing in all the available fusion-positive cases.8,9 It is thus 
unlikely that sensitivity would be significantly less in 
the cohort with full presentation of negatively to weakly 
stained cases. Furthermore, the same applies also to 
estimated staining specificity (88% in the sequencing 
cohort), as exclusion of most of the negatively to weakly 
stained cases tends to lead to underestimation of stain-
ing specificity.
Positive FGFR3 staining was generally heterogeneous. 
While positive staining was typically less predominant 
and associated with lower cellularity in fusion-negative 
tumors, negatively stained malignant regions were also 
detected in a proportion of fusion-positive cases (Fig. 4A). 
This is relevant from a treatment perspective, as negative 
cells are unlikely to respond to targeted treatment, poten-
tially resulting in treatment failures with FGFR inhibitors. 
Variable expression levels and negative subclones may 
also explain why partial responses have been observed in 
clinical trials.9,22 Further characterization of FGFR3-negative 
cells is important for improved treatment.
In this study, FGFR3 fusions always involved 3' fusion 
partners with dimerization domains, and no FGFR3 stain-
ing was detected in the majority of samples (Fig. 1), which 
supports our previous finding that loss of 3' UTR and miR-
99a mediated suppression is needed for expression and 
oncogenicity of the fusion protein in diffuse gliomas.8 
Although FGFR3 is mostly fused to TACC3, other fusion 
partners also exist. If PCR-based tools for detecting gene 
fusions are used as the sole diagnostic method for fusion 
detection, cases with alternative 3' partners will be missed 
during diagnosis. On the other hand, FGFR3 staining does 
not require pre-knowledge of fusion partners and is fully 
FFPE compatible together with our targeted sequencing 
approach. It will also be interesting to determine whether 
the IHC approach is suitable for fusion detection in other 
malignancies with low endogenous FGFR3 expression, 
such as in lung squamous cell carcinoma.20
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online.
Funding
This work was supported by grants from the Academy of 
Finland (grants 259038 to K.G., 269474 to M.N., and 251790 to 
O.Y.H.), the Emil Aaltonen Foundation (M.A.), the Päivikki ja 
Sakari Sholberg Foundation (K.G.), the Finnish Funding Agency 
for Technology and Innovation Finland Distinguished Professor 
program, Competitive State Research Financing of the Expert 
Responsibility area of Tampere University Hospital (J.H., H.H., 
grant 9T042 to M.N.), and funding from the US National Cancer 
Institute (R01 CA183153 to W.Z.). W.Z.  is supported by the 
endowed Hanes and Willis Family Professorship in Cancer.
Acknowledgments
We highly appreciate Marika Vähä-Jaakkola, Paula Kosonen, 
Päivi Martikainen, Marja Pirinen, Katja Liljeström, Riina Kylätie, 
Dr. Leena Latonen, Osku Alanen, Maria Laaksonen, Dr. Eloise 
Mikkonen, Riitta Koivisto, Dr. Joanna Ilvesaro, and Satu Salo for 
their help in sample handling. Personnel at Tampere University 
Hospital and Fimlab laboratories are acknowledged for their 
contribution to sample collection. We acknowledge the CSC 
IT Centre for Science, Finland, for computational resources 
and Ann M.  Sutton (Department of Scientific Publications, 
University of Texas MD Anderson Cancer Center) for editing this 
manuscript.
Conflict of interest statement. The authors have no conflicts of 
interest to disclose.
References
1. Cancer Genome Atlas Research Network. Comprehensive, integrative 
genomic analysis of diffuse lower-grade gliomas. New Engl J Med. 
2015;372(26):2481–2498.
2. Brennan CW, Verhaak RG, McKenna A, et  al.; TCGA Research 
Network. The somatic genomic landscape of glioblastoma. Cell. 
2013;155(2):462–477.
3. Suzuki H, Aoki K, Chiba K, et al. Mutational landscape and clonal archi-
tecture in grade II and III gliomas. Nat Genet. 2015;47(5):458–468.
4. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 
mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 
2009;27(25):4150–4154.
5. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK ed. WHO Classification 
of Tumours of the Central Nervous System WHO/IARC Classification 
of Tumours, 4th edition revised. Geneva, Switzerland: World Health 
Organization; 2016.
6. Ceccarelli M, Barthel FP, Malta TM, et  al.; TCGA Research Network. 
Molecular profiling reveals biologically discrete subsets and pathways 
of progression in diffuse glioma. Cell. 2016;164(3):550–563.
7. Singh D, Chan JM, Zoppoli P, et al. Transforming fusions of FGFR and TACC 
genes in human glioblastoma. Science. 2012;337(6099):1231–1235.
Downloaded from https://academic.oup.com/neuro-oncology/article-abstract/19/9/1206/3098170/Strong-FGFR3-staining-is-a-marker-for-FGFR3
by Tampere University Library. Department of Health Sciences user
on 25 August 2017
 1216 Granberg et al. Strong FGFR3 staining marks FGFR3 fusions
8. Parker BC, Annala MJ, Cogdell DE, et al. The tumorigenic FGFR3-TACC3 
gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest. 
2013;123(2):855–865.
9. Di Stefano AL, Fucci A, Frattini V, et al. Detection, characterization, and 
inhibition of FGFR-TACC fusions in IDH wild-type glioma. Clin Cancer 
Res. 2015;21(14):3307–3317.
10. Parker BC, Engels M, Annala M, Zhang W. Emergence of FGFR family 
gene fusions as therapeutic targets in a wide spectrum of solid tumours. 
J Pathol. 2014;232(1):4–15.
11. Rand V, Huang J, Stockwell T, et al. Sequence survey of receptor tyrosine 
kinases reveals mutations in glioblastomas. Proc Natl Acad Sci U S A. 
2005;102(40):14344–14349
12. Jones DT, Hutter B, Jäger N, et  al.; International Cancer Genome 
Consortium PedBrain Tumor Project. Recurrent somatic altera-
tions of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet. 
2013;45(8):927–932.
13. Zhang J, Wu G, Miller CP, et al.; St. Jude Children’s Research Hospital–
Washington University Pediatric Cancer Genome Project. Whole-
genome sequencing identifies genetic alterations in pediatric low-grade 
gliomas. Nat Genet. 2013;45(6):602–612.
14. Parker BC, Zhang W. Fusion genes in solid tumors: an emerging target for 
cancer diagnosis and treatment. Chin J Cancer. 2013;32(11):594–603.
15. Capelletti M, Dodge ME, Ercan D, et  al. Identification of recurrent 
FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma. Clin Cancer 
Res. 2014;20(24):6551–6558.
16. Wang R, Wang L, Li Y, et al. FGFR1/3 tyrosine kinase fusions define a 
unique molecular subtype of non-small cell lung cancer. Clin Cancer Res. 
2014;20(15):4107–4114.
17. Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR 
landscape in cancer: Analysis of 4,853 tumors by next-generation 
sequencing. Clin Cancer Res. 2016;22(1):259–267.
18. Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in 
bladder cancer. Hum Mol Genet. 2013;22(4):795–803.
19. Wu YM, Su F, Kalyana-Sundaram S, et al. Identification of targetable 
FGFR gene fusions in diverse cancers. Cancer Discov. 2013;3(6):636–647.
20. Majewski IJ, Mittempergher L, Davidson NM, et  al. Identification of 
recurrent FGFR3 fusion genes in lung cancer through kinome-centred 
RNA sequencing. J Pathol. 2013;230(3):270–276.
21. Dienstmann R, Rodon J, Prat A, et al. Genomic aberrations in the FGFR 
pathway: opportunities for targeted therapies in solid tumors. Ann 
Oncol. 2014;25(3):552–563.
22. Tabernero J, Bahleda R, Dienstmann R, et al. Phase I dose-escalation 
study of JNJ-42756493, an oral pan-fibroblast growth factor recep-
tor inhibitor, in patients with advanced solid tumors. J Clin Oncol. 
2015;33(30):3401–3408.
23. Lewin J, Siu LL. Development of fibroblast growth factor receptor inhibi-
tors: kissing frogs to find a prince? J Clin Oncol. 2015;33(30):3372–3374.
24. Sallinen SL, Sallinen PK, Haapasalo HK, et al. Identification of differen-
tially expressed genes in human gliomas by DNA microarray and tissue 
chip techniques. Cancer Res. 2000;60(23):6617–6622.
25. Järvelä S, Parkkila S, Bragge H, et al. Carbonic anhydrase IX in oligoden-
droglial brain tumors. BMC Cancer. 2008;8:1.
26. Nordfors K, Haapasalo J, Mäkelä K, et al. Twist predicts poor outcome 
of patients with astrocytic glioma. J Clin Pathol. 2015;68(11):905–912.
27. Haapasalo H, Sallinen S, Sallinen P, et al. Clinicopathological correlation 
of cell proliferation, apoptosis and p53 in cerebellar pilocytic astrocyto-
mas. Neuropathol Appl Neurobiol. 1999;25(2):134–142.
28. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. 
Nat Methods. 2012;9(4):357–359.
29. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of 
genetic variants from high-throughput sequencing data. Nucleic Acids 
Res. 2010;38(16):e164.
30. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing 
genomic features. Bioinformatics. 2010;26(6):841–842.
31. Lin CR, Kapiloff MS, Durgerian S, et al. Molecular cloning of a brain-
specific calcium/calmodulin-dependent protein kinase. Proc Natl Acad 
Sci U S A. 1987;84(16):5962–5966.
32. Yamauchi T. Neuronal Ca2+/calmodulin-dependent protein kinase II–
discovery, progress in a quarter of a century, and perspective: implica-
tion for learning and memory. Biol Pharm Bull. 2005;28(8):1342–1354.
33. Kasashima K, Sakashita E, Saito K, Sakamoto H. Complex formation of 
the neuron-specific ELAV-like Hu RNA-binding proteins. Nucleic Acids 
Res. 2002;30(20):4519–4526.
34. Bao ZS, Chen HM, Yang MY, et al. RNA-seq of 272 gliomas revealed a 
novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblasto-
mas. Genome Res. 2014;24(11):1765–1773.
35. Göke F, Franzen A, Hinz TK, et  al. FGFR1 expression levels predict 
BGJ398 sensitivity of FGFR1-dependent head and neck squamous cell 
cancers. Clin Cancer Res. 2015;21(19):4356–4364.
36. Wynes MW, Hinz TK, Gao D, et al. FGFR1 mRNA and protein expression, 
not gene copy number, predict FGFR TKI sensitivity across all lung cancer 
histologies. Clin Cancer Res. 2014;20(12):3299–3309.
Downloaded from https://academic.oup.com/neuro-oncology/article-abstract/19/9/1206/3098170/Strong-FGFR3-staining-is-a-marker-for-FGFR3
by Tampere University Library. Department of Health Sciences user
on 25 August 2017
